UCB’s Post

📰 Great article by William A Haseltine showing how light therapy is being used to potentially treat #alzheimers disease. Exciting to see more companies investing in the research to promote light therapy. ❔Did you know? Light therapy on a fundamental level can increase blood flow and cellular activity while also decreasing inflammation! 🧠 #innovation #technology #lighttherapy Neuronic 🔗 Article Link below: https://lnkd.in/ekezQ9cu

🗞 In case you missed it... Yesterday, Minoryx Therapeutics shared positive results from a compassionate use study of #leriglitazone* for the treatment of progressive #cALD - a rare, fatal neurodegenerative disorder affecting the brain. 📰 Read more about it with the official release, linked via the post below. 🔬 Read the full study here: https://bit.ly/3KGp7ow 📽 Watch the video summary of the study, here: https://bit.ly/3XeStlh *Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases.

On the eve of Rare Disease Day, we're celebrating the landmark EU approval of the first treatment for Friedreich's Ataxia in Europe. Despite falling under the "rare disease" umbrella, Friedreich's Ataxia (FA) is the most common form of ataxia worldwide, affecting an estimated 1 in every 30,000 people. It causes progressive neurological symptoms from childhood, including ataxia (muscle co-ordination difficulties), weakness, altered sensations and impaired speech, and can also cause problems with the heart. With limited treatments and an average life expectancy of around 37, the landmark approval of Skyclarys (omaveloxolone) in the EU provides new hope for FA patients. Key highlights include: • Skyclarys is thought to work by decreasing neuronal susceptibility to oxidative stress via the Nrf2 pathway, and demonstrated improved clinical scores in a 48-week study, relative to placebo • Early work performed on cell models demonstrated the beneficial effect of omaveloxolone on mitochondrial activity and oxidative stress • With the EU approval, Biogen Inc. can now work towards bringing new hope for FA patients, while opening up a new avenue for FA drug discovery Click here to read more: https://hubs.la/Q02mvRKx0 #iPSCs #FriedreichsAtaxia #DrugDiscovery #RareDiseaseDay #AtaxiaResearch

On the eve of Rare Disease Day, we're celebrating the landmark EU approval of the first treatment for Friedreich's Ataxia in Europe. Despite falling under the "rare disease" umbrella, Friedreich's Ataxia (FA) is the most common form of ataxia worldwide, affecting an estimated 1 in every 30,000 people. It causes progressive neurological symptoms from childhood, including ataxia (muscle co-ordination difficulties), weakness, altered sensations and impaired speech, and can also cause problems with the heart. With limited treatments and an average life expectancy of around 37, the landmark approval of Skyclarys (omaveloxolone) in the EU provides new hope for FA patients. Key highlights include: • Skyclarys is thought to work by decreasing neuronal susceptibility to oxidative stress via the Nrf2 pathway, and demonstrated improved clinical scores in a 48-week study, relative to placebo • Early work performed on cell models demonstrated the beneficial effect of omaveloxolone on mitochondrial activity and oxidative stress • With the EU approval, Biogen Inc. can now work towards bringing new hope for FA patients, while opening up a new avenue for FA drug discovery Click here to read more: https://hubs.la/Q02mvP9R0 #iPSCs #FriedreichsAtaxia #DrugDiscovery #RareDiseaseDay #AtaxiaResearch

Looking for a new treatment option for severe blood disorders of the bone marrow? Check out this informative article published by ScienceDaily. Learn about the latest research on myelodysplastic neoplasms and how it could provide hope for patients with limited treatment options.

In this new article, Jay Lombard, Dr. Kiran Dintyala AKA Dr. Calm, and Niranjan Kumar, PDF, Ph.D. MTM(Management, UPENN) discuss the link between periodontal disease and systemic disorders, focusing most on the association between proteases and neurological dysfunction. Therapeutic measures can target these pathological pathways, they write: https://lnkd.in/e9RywDmN #drugtargeting #drugdiscovery #periodontitis #neurologicaldisease

Exciting breakthrough in multiple sclerosis (MS) ! 🧬 Multiple sclerosis (MS) affects nearly a million Americans and is characterized by chronic inflammation of the central nervous system (CNS). Unique autoantibodies against the body's own proteins appear years before symptoms in about 10% of cases, potentially explaining immune attacks on the CNS. 🔬 University of California, San Francisco (UCSF) scientists have developed a diagnostic method using PhIP-Seq to detect these autoantibodies in blood samples, published in Nature Medicine. ⏳ Early detection of these autoantibodies offers hope for earlier intervention and treatment, potentially slowing disease progression. 💊 These findings open new avenues for understanding and treating MS, with the potential to move from suppression to cure. #MedicalBreakthrough #Innovation #Healthtech ➡️ Read this article for more details: https://lnkd.in/eS38hf7Z

Contextualising the benefits and risks of anti‐amyloid therapy for patients with Alzheimer disease and their care team: https://ow.ly/iVRB50SsvHs

Patients affected by chronic inflammatory demyelinating polyradiculoneuropathy require close follow up due to the neuronal demyelination along with axonal degeneration associated with the disease process, giving the opportunity to the medical team of adequating therapeutics and other medical interventions, according to the evolution of the symptoms, to prevent irreversible axonal degeneration. #CIDP #Polineuropathy #demyelinatingdiseases

Our latest review article lays the groundwork for treating and slowing neurodegenerative diseases by targeting and repairing ECM collagen in the central nervous system. Very proud to be associated with this team of researchers! https://lnkd.in/eX4cntpQ